Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 8/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 4/20 | 0.42 |
| ▸ | NPY4R | P50391 | 4/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | NPY1R | P25929 | 3/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402784 | 0.88 | TFPI (0.51) | TFPIEP300HIF1ANPY2RNPY4R | |
| SCHEMBL16326684 | 0.88 | TFPI (0.51) | TFPIEP300HIF1ANPY2RNPY4R | |
| SCHEMBL13402781 | 0.78 | TFPI (0.45) | TFPIEP300HIF1ANPY2RNPY4R | |
| SCHEMBL31437204 | 0.75 | EPHA2 (0.48) | CXCR4 | |
| SCHEMBL29693008 | 0.75 | OPRM1 (0.50) | MAPK8MAPK9MAPK10 | |
| SCHEMBL30540072 | 0.74 | OPRM1 (0.50) | — | |
| SCHEMBL31437206 | 0.73 | EPHA2 (0.47) | TFPIMAPK8MAPK9MAPK10CXCR4 | |
| SCHEMBL31437173 | 0.73 | EPHA2 (0.47) | TFPIMAPK8MAPK9MAPK10CXCR4 | |
| SCHEMBL31437170 | 0.73 | EPHA2 (0.44) | CXCR4KDM1A | |
| SCHEMBL31321048 | 0.73 | REN (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | EPOR, LIFR, LNPEP | TFPI 4255/4885EP300 4604/4885HIF1A 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.